Reversal of 5-flouroucial Resistance by Adenovirus-mediated Transfer of Wild-type P53 Gene in Multidrug-resistant Human Colon Carcinoma LoVo/5-FU Cells

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2004 Jun 29

PMID 15222051

Citations 6

Authors

Zhi-Wei Yu

Peng Zhao

Ming Liu

Xin-Shu Dong

Ji Tao

Xue-Qin Yao

Xin-Hua Yin

Yu Li

Song-Bin Fu

Affiliations

Soon will be listed here.

Abstract

Aim: To observe the reversal effects of wide-type p53 gene on multi-drug resistance to 5-FU (LOVO/5-FU).

Methods: After treatment with Ad-p53, LOVO/5-FU sensitivity to 5-Fu was investigated using tetrazolium dye assay. Multidrug resistance gene-1 (MDR1) gene expression was assayed by semi-quantitative reverse transcription-polymerase chain reaction and the expression of p53 protein was examined by Western blotting.

Results: The reversal activity after treatment with wide-type p53 gene was increased up to 4.982 fold at 48 h. The expression of MDR1 gene decreased significantly after treatment with wide-type p53 gene, and the expression of p53 protein lasted for about 5 d, with a peak at 48 h, and began to decrease at 72 h.

Conclusion: Wide-type p53 gene has a remarkable reversal activity for the high expression of MDR1 gene in colorectal cancers. The reversal effects seem to be in a time dependent manner. It might have good prospects in clinical application.

Citing Articles

Therapeutic strategies targeting Wnt/β‑catenin signaling for colorectal cancer (Review).

Ji Y, Lv J, Sun D, Huang Y Int J Mol Med. 2021; 49(1).

PMID: 34713301 PMC: 8589460. DOI: 10.3892/ijmm.2021.5056.

Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment.

Marin J, Macias R, Monte M, Herraez E, Peleteiro-Vigil A, Sanchez de Blas B Cancers (Basel). 2020; 12(9).

PMID: 32933095 PMC: 7563523. DOI: 10.3390/cancers12092605.

p53 and metabolism: from mechanism to therapeutics.

Simabuco F, Morale M, Pavan I, Morelli A, Silva F, Tamura R Oncotarget. 2018; 9(34):23780-23823.

PMID: 29805774 PMC: 5955117. DOI: 10.18632/oncotarget.25267.

Inhibition of transient receptor potential channel 5 reverses 5-Fluorouracil resistance in human colorectal cancer cells.

Wang T, Chen Z, Zhu Y, Pan Q, Liu Y, Qi X J Biol Chem. 2014; 290(1):448-56.

PMID: 25404731 PMC: 4281746. DOI: 10.1074/jbc.M114.590364.

Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells.

Hummel R, Watson D, Smith C, Kist J, Michael M, Haier J J Gastrointest Surg. 2011; 15(3):429-38.

PMID: 21246413 DOI: 10.1007/s11605-011-1418-9.

References

Zambetti G, Levine A . A comparison of the biological activities of wild-type and mutant p53. FASEB J. 1993; 7(10):855-65. DOI: 10.1096/fasebj.7.10.8344485. View

Yuan R, Meng Q, Hu H, Goldberg I, Rosen E, Fan S . P53-independent downregulation of p73 in human cancer cells treated with Adriamycin. Cancer Chemother Pharmacol. 2001; 47(2):161-9. DOI: 10.1007/s002800000196. View

Cho Y, Gorina S, Jeffrey P, Pavletich N . Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994; 265(5170):346-55. DOI: 10.1126/science.8023157. View

Shapiro A, Ling V . Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol. 1997; 53(4):587-96. DOI: 10.1016/s0006-2952(96)00826-x. View

Mohr L, Geissler M . [Gene therapy: new developments]. Praxis (Bern 1994). 2003; 91(51-52):2227-35. DOI: 10.1024/0369-8394.91.51.2227. View

Zastawny R, Salvino R, Chen J, Benchimol S, Ling V . The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene. 1993; 8(6):1529-35. View

Wolcke J, Reimann M, Klumpp M, Gohler T, Kim E, Deppert W . Analysis of p53 "latency" and "activation" by fluorescence correlation spectroscopy. Evidence for different modes of high affinity DNA binding. J Biol Chem. 2003; 278(35):32587-95. DOI: 10.1074/jbc.M303615200. View

Liedtke C, Groger N, Manns M, Trautwein C . The human caspase-8 promoter sustains basal activity through SP1 and ETS-like transcription factors and can be up-regulated by a p53-dependent mechanism. J Biol Chem. 2003; 278(30):27593-604. DOI: 10.1074/jbc.M304077200. View

Seto E, Usheva A, Zambetti G, Momand J, Horikoshi N, Weinmann R . Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A. 1992; 89(24):12028-32. PMC: 50691. DOI: 10.1073/pnas.89.24.12028. View

10.

Tsuruo T . Molecular cancer therapeutics: recent progress and targets in drug resistance. Intern Med. 2003; 42(3):237-43. DOI: 10.2169/internalmedicine.42.237. View

11.

Chin K, Ueda K, Pastan I, Gottesman M . Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992; 255(5043):459-62. DOI: 10.1126/science.1346476. View

12.

Bush J, Li G . Regulation of the Mdr1 isoforms in a p53-deficient mouse model. Carcinogenesis. 2002; 23(10):1603-7. DOI: 10.1093/carcin/23.10.1603. View

13.

Yazlovitskaya E, DeHaan R, Persons D . Prolonged wild-type p53 protein accumulation and cisplatin resistance. Biochem Biophys Res Commun. 2001; 283(4):732-7. DOI: 10.1006/bbrc.2001.4849. View

14.

Thomas H, Coley H . Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 2003; 10(2):159-65. DOI: 10.1177/107327480301000207. View

15.

Durie B, Dalton W . Reversal of drug-resistance in multiple myeloma with verapamil. Br J Haematol. 1988; 68(2):203-6. DOI: 10.1111/j.1365-2141.1988.tb06190.x. View

16.

Abu-Qare A, Elmasry E, Abou-Donia M . A role for P-glycoprotein in environmental toxicology. J Toxicol Environ Health B Crit Rev. 2003; 6(3):279-88. DOI: 10.1080/10937400306466. View

17.

Zhu X, Li J, Xia X, Zhu M, Geng M, Chen L . [Multidrug resistance mechanisms in cell line HL-60/VCR]. Ai Zheng. 2003; 21(12):1310-3. View

18.

Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H . Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003; 94(1):15-21. PMC: 11160265. DOI: 10.1111/j.1349-7006.2003.tb01345.x. View

19.

Sowa Y, Sakai T . [Gene-regulating chemoprevention against cancer--as a model for "molecular-targeting prevention" of cancer]. Nihon Eiseigaku Zasshi. 2003; 58(2):267-74. DOI: 10.1265/jjh.58.267. View

20.

Chang B, Swift M, Shen M, Fang J, Broude E, Roninson I . Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci U S A. 2001; 99(1):389-94. PMC: 117570. DOI: 10.1073/pnas.012602599. View